
About
About Me
Building Solid Ventures around Products with High Patient Value
Hannah Teichmann is Chief Clinical Officer at Robeauté, where she leads global clinical strategy and evidence generation for Robeauté
I am a strategic leader able to drive the growth of medtech companies and products that make a significant positive difference in people's lives.
In everything I do, I combine the rigorous thinking and analytical methodology from my natural sciences background with the long-term vision of a founder mindset and the skills of a process and organization-oriented, leader and board member.
In my seven years of board membership, I have worked with top MedTech leaders in robotic surgery, neuromodulation and regenerative medicine, balancing the needs and interests of all corporate stakeholders. I am a proven team-builder and team-player, unafraid of taking on new challenges.
In my founder experience, starting from an original idea, I was instrumental in delivering a unique new robotics product to hospitals in a company that grew to one hundred employees in 6 years. In the course of this I secured capital of over EUR 40M from Angel investors, VC funds and non-dilutive funding, from initial outreach and pitches through term sheets, due diligence, investment docs and closings. My passions are strategically building products and companies by identifying clinical needs that represents a unique market opportunity using a strong data-backed approach.
I have driven product development and company growth while working hand-in-hand with the community of physician and patient end-users. I am a German and US national and have lived and worked in California, Germany, Great Britain and Italy, gaining a unique multicultural experience allowing me to work effectively with teams internationally.





Key Achievements
Surgical Robotics
-
Co-founder, Board Member and VP Clinical Development & Medical Affairs at MMI Inc. until Nov. 2021.
-
Instrumental in defining product-market fit and validating it with the user community.
-
Hired and lead a team of Clinical Engineers to drive MMI's product development from a Clinical standpoint, coordinating with surgeon end-users on product specifications, device validation and definition of clinical applications based on surgical and market metrics .
-
Design and execute Clinical Strategy for First Indication (Reconstructive Surgery) with internal and external stakeholders, from First-in-human (MDD/MDR) to PMCF (MDD/MDR) and FDA study design.
Neurotech
-
Strategic Development of New Indication, reporting to CEO.
-
Development of new therapies in psychiatry, neurology and neuromodulation.
-
Support of the strategic choice of indication and development of a new indication of an implantable neurotechnology.
-
Market sizing and reimbursement analysis by geography and indication.
-
Strategic KOL network development.
-
Development of Business Case for investment in developing the indication.
-
Clinical study design, development, submission and approval in collaboration with CRO and KOLs.
-
Device design and development from concept through to V&V with internal R&D team and external suppliers.